Supernus Pharma (SUPN) Misses Q3 EPS by 32c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of $172.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• MP Materials seen largely insulated after China export-control move